Thousand Oaks, California, USA

Amgen

American biotechnology company developing maridebart cafraglutide (MariTide), an investigational once-monthly obesity treatment that combines GLP-1 receptor activation with GIP receptor blocking. Amgen's second-quarter 2026 results release lists MariTide Phase 3 trials as ongoing or enrolling. It is not approved.

2025 revenue

Amgen reported total revenues of $36,751 million for 2025, up 10% from $33,424 million in 2024 (product sales $35,148 million plus other revenues $1,603 million).[src]

MariTide description and status

Amgen describes MariTide (maridebart cafraglutide) as an antibody-peptide conjugate that activates the GLP-1 receptor and blocks the GIP receptor. In its second-quarter 2026 release Amgen listed Phase 3 studies for chronic weight management (MARITIME-1 and MARITIME-2) as ongoing, with further Phase 3 studies enrolling. It is investigational and not approved.[src]

Phase 2 trial published

A phase 2 trial of once-monthly maridebart cafraglutide in 592 adults was published in the New England Journal of Medicine (online in June 2025; print issue dated 4 September 2025). The trial was funded by Amgen. At 52 weeks, mean weight change in adults with obesity ranged from -12.3% to -16.2% with the drug versus -2.5% with placebo (treatment-policy estimand). Gastrointestinal side effects were common.[src]